Update from UNITY Biotechnology. SC clearance to treat osteoarthritis to enter Phase I in H1 2018. Also, Unity will start working on other aging research paths beyond SC clearance: mitochondrial dysfunction and loss of circulating youth factors.


About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website, NutritionTheory.org

View all posts by Robert Zinn →